Lupin is trading at RS. 2033.50, rising by 19.70 points or 0.98% from its previous close of RS. 2013.80 on the BSE.

The stock opened at RS. 1989.20 and touched an intraday high of RS. 2047.80 and a low of RS. 1976.30. So far, 12,387 shares have changed hands on the counter.

Classified under BSE group 'A', the stock with a face value of RS. 2 has recorded a 52-week high of RS. 2403.45 on January 2, 2025, and a 52-week low of RS. 1493.75 on June 4, 2024. Over the past week, the scrip has seen highs and lows of RS. 2099.85 and RS. 1976.30 respectively. The current market capitalization stands at RS. 93047.04 crore.

The company's shareholding pattern comprises 46.92% held by promoters, 46.88% by institutional investors, and 6.20% by non-institutional investors.

Lupin has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Raltegravir Tablets USP, 600 mg. These tablets are bioequivalent to Isentress HD Tablets, 600 mg, marketed by Merck Sharp & Dohme LLC. Lupin is the exclusive first-to-file applicant for this product, granting it 180 days of generic marketing exclusivity in the U.S.

The tablets will be manufactured at Lupin’s Nagpur facility in India. Raltegravir is used in combination with other antiretroviral agents for treating HIV-1 infection in adults and pediatric patients weighing at least 40 kg. The reference drug had estimated annual U.S. sales of $34 million as per IQVIA MAT March 2025.

Lupin is a globally recognized, innovation-driven pharmaceutical company focused on developing and marketing a wide range of branded and generic drugs, biotechnology products, and active pharmaceutical ingredients (APIs).